Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809430 | 0.88 | CACNA1B (0.50) | HSD11B1CACNA1BMGLLSCN9ATP53 | |
| SCHEMBL1811520 | 0.81 | CACNA1B (0.50) | HSD11B1CACNA1BMGLLSCN9ATP53 | |
| SCHEMBL12099411 | 0.77 | CACNA1B (0.33) | HSD11B1CACNA1B | |
| SCHEMBL12188744 | 0.75 | HTR2A (0.41) | CACNA1BMGLLDRD2 | |
| SCHEMBL12100617 | 0.74 | HSD11B1 (0.41) | HSD11B1CACNA1BMGLLSCN9A | |
| SCHEMBL1811395 | 0.72 | HTR2A (0.49) | HSD11B1MGLLDRD2 | |
| SCHEMBL1810763 | 0.69 | AHR (0.49) | — | |
| SCHEMBL22516906 | 0.69 | DRD2 (0.48) | SCN9ADRD2DRD3SYK | |
| SCHEMBL12188773 | 0.67 | KDM4E (0.45) | MGLLTP53DRD2 | |
| SCHEMBL22516913 | 0.67 | AHR (0.47) | SCN9ATP53DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | HSD11B1 2985/4885CACNA1B 17/4885MGLL 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.